Höll K, Deisenhammer E, Dauth J, Carmann H, Schubiger P A
Department of Neuronuclear Medicine and Neurophysiology, Wagner-Jauregg Hospital, Linz, Switzerland.
Int J Rad Appl Instrum B. 1989;16(8):759-63. doi: 10.1016/0883-2897(89)90158-x.
Recently, [123I]Ro16-0154 has been introduced as a potential benzodiazepine (BZD) receptor imaging tracer for SPECT. We investigated the biodistribution of [123I]Ro16-0154 in humans and compared it with the animal data. There was a rapid and high 123I-uptake in the brain comparable to rCBF. In the following images, however, regionally different changes were observed, resulting in a subsequent intracerebral retention parallel to the known distribution of BZD receptors. The results suggest that [123I]Ro16-0154 is of potential clinical use as a BZD receptor imaging agent.
最近,[123I]Ro16 - 0154已被引入作为一种潜在的用于单光子发射计算机断层扫描(SPECT)的苯二氮䓬(BZD)受体显像剂。我们研究了[123I]Ro16 - 0154在人体中的生物分布,并将其与动物数据进行了比较。大脑中存在与局部脑血流量(rCBF)相当的快速且高度的123I摄取。然而,在随后的图像中,观察到了区域差异变化,导致随后脑内滞留情况与已知的BZD受体分布平行。结果表明,[123I]Ro16 - 0154作为一种BZD受体显像剂具有潜在的临床应用价值。